Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177 LuPSMA-617 vs Docetaxel in Metastatic Castration-Resistant Prostate Cancer
NCT04663997Phase 2Active, not recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Aug 2021
- Primary completion
- Aug 2025
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Canadian Cancer Trials Group. Primary endpoint: Progression-free survival at 3 years. Started Aug 2021; status: active, not recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04663997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04663997.